Orchid Pharma annual profit drops to ₹45.2 crore
The company reported a sharp decline in annual standalone profit as auditors flagged unaudited US subsidiaries in the consolidated results.
— 6 earlier stories on Orchid Pharma Ltd. →What's new
- Standalone annual net profit fell to ₹45.2 crore from ₹106.5 crore in the prior year.
- Q4 standalone profit reached ₹30.6 crore, recovering from a Q3 loss.
- Consolidated results carry a qualified audit opinion regarding unaudited US subsidiaries.
Why this matters
The earnings erosion was expected, but the qualified audit opinion on consolidated results introduces a layer of uncertainty regarding the company's US operations. Investors should look past the Q4 recovery to the structural decline in annual profitability.
What we're watching
- Any clarification on the status of the US subsidiaries.
- Management commentary on the sustainability of the Q4 profit rebound.
- Resolution of the audit qualification in future filings.
The full read
Orchid Pharma closed the fiscal year with a standalone net profit of ₹45.2 crore. This is a sharp decline from the ₹106.5 crore recorded in the previous year. While the company managed a Q4 standalone profit of ₹30.6 crore—recovering from a loss in the preceding quarter—the broader annual trend remains weak. Consolidated financial results carry a qualified audit opinion. This qualification specifically cites the lack of audits for the company's US subsidiaries. These figures align with prior guidance and quarterly disclosures, offering no surprises for investors. The appointment of an internal auditor was also confirmed as a standard procedural step. The primary issue remains the quality of the consolidated reporting, which is currently hampered by the unaudited status of international units. It is a messy finish to the year.
Questions answered
- How did Orchid Pharma's annual profit compare to the previous year?
- Standalone annual net profit dropped to ₹45.2 crore from ₹106.5 crore in the previous fiscal year.
- What is the status of the company's Q4 performance?
- The company posted a standalone profit of ₹30.6 crore for Q4, marking a recovery from the loss reported in Q3.
- Why did the auditors qualify the consolidated results?
- The audit opinion is qualified because the company's US subsidiaries remain unaudited.
- Are these results a surprise to the market?
- No. The earnings erosion was previously signaled and largely anticipated by the market based on earlier quarterly disclosures.
Orchid Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on ORCHPHARMA →- 25 May 2026 · 9:14 PM IST Orchid Pharma annual profit drops to ₹45.2 crore
- 3d ago Orchid lands Russian partner for Exblifep; $178M over 10 years
- 35d ago NCLT clears Orchid-Dhanuka merger. Integration starts now.
- 39d ago Orchid expects Enmetazobactam deal this quarter, eyes US sterile market
- 45d ago Orchid Pharma lifts Enmetazobactam lifetime sales target to $2 billion